Showing 1765 results
-
Ad hoc release /Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple…
-
Press release /After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor…
-
Press release /Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta…
-
Press release /Latest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2 Moderate-to-severe psoriasis affects more than…
-
Press release /Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights…
-
Press release /Promacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low…
-
Ad hoc release /Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
-
Press release /Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya® (fingolimod) 0.5mg had significantly fewer relapses than patients…
-
Press release /Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no…
-
Press release /New oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12…